



## Successful test of Wageningen Covid vaccine

Tests with SI-VLP, the Wageningen coronavirus vaccine, have been successful. Even a low dose produced a good immune response in mice. The Wageningen research groups Virology, Bioprocess Technology and Biochemistry published this result in early October in *mBio*.

The vaccine, a protein that is made in the cells of a moth, can be produced on a large scale: a single bioreactor with insect cells can supply a million doses. Danish partners of the Wageningen researches have also developed a similar protein vaccine, ABNCoV2, which was tested earlier this year in a clinical trial by Radboud University Medical Centre in Nijmegen. It is now in the final trial phase. If that too is successful, the pharmaceutical company Bavarian Nordic will bring it on the market.

Info: [gorben.pijlman@wur.nl](mailto:gorben.pijlman@wur.nl)